IBDEI1JW ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24788,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24788,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,24788,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,24788,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,24789,0)
 ;;=C91.40^^107^1211^80
 ;;^UTILITY(U,$J,358.3,24789,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24789,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,24789,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,24789,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,24790,0)
 ;;=C91.42^^107^1211^78
 ;;^UTILITY(U,$J,358.3,24790,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24790,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,24790,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,24790,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,24791,0)
 ;;=C91.41^^107^1211^79
 ;;^UTILITY(U,$J,358.3,24791,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24791,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,24791,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,24791,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,24792,0)
 ;;=D57.01^^107^1211^81
 ;;^UTILITY(U,$J,358.3,24792,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24792,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,24792,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,24792,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,24793,0)
 ;;=D57.00^^107^1211^82
 ;;^UTILITY(U,$J,358.3,24793,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24793,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,24793,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,24793,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,24794,0)
 ;;=D57.02^^107^1211^83
 ;;^UTILITY(U,$J,358.3,24794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24794,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,24794,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,24794,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,24795,0)
 ;;=D68.32^^107^1211^85
 ;;^UTILITY(U,$J,358.3,24795,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24795,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,24795,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,24795,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,24796,0)
 ;;=C22.2^^107^1211^86
 ;;^UTILITY(U,$J,358.3,24796,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24796,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,24796,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,24796,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,24797,0)
 ;;=D58.9^^107^1211^88
 ;;^UTILITY(U,$J,358.3,24797,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24797,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,24797,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,24797,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,24798,0)
 ;;=C81.99^^107^1211^89
 ;;^UTILITY(U,$J,358.3,24798,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24798,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,24798,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,24798,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,24799,0)
 ;;=C81.90^^107^1211^90
 ;;^UTILITY(U,$J,358.3,24799,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24799,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,24799,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,24799,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,24800,0)
 ;;=D89.2^^107^1211^91
 ;;^UTILITY(U,$J,358.3,24800,1,0)
 ;;=^358.31IA^4^2
